{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:20Z","timestamp":1707525320113},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"DOI":"10.7759\/cureus.46478","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T16:41:57Z","timestamp":1696437717000},"source":"Crossref","is-referenced-by-count":0,"title":["Managing a Patient Presenting With Chest Pain and Gastrointestinal Complaints Using Dupilumab"],"prefix":"10.7759","author":[{"given":"Kayla L","family":"Alaimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren N","family":"Ramcharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver G","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards IR","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000, 356:1255-9. 10.1016\/s0140-6736(00)02799-9","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272743","article-title":"Adverse drug events leading to emergency department visits: a multicenter observational study in Korea","volume":"17","author":"Kang MG","year":"2022","unstructured":"Kang MG, Lee JY, Woo SI, et al.. Adverse drug events leading to emergency department visits: a multicenter observational study in Korea. PLoS One. 2022, 17:e0272743. 10.1371\/journal.pone.0272743","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.07.041","article-title":"National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents","volume":"152","author":"Cohen AL","year":"2008","unstructured":"Cohen AL, Budnitz DS, Weidenbach KN, Jernigan DB, Schroeder TJ, Shehab N, Pollock DA. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. J Pediatr. 2008, 152:416-21. 10.1016\/j.jpeds.2007.07.041","journal-title":"J Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck LA","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al.. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014, 371:130-9. 10.1056\/NEJMoa1314768","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.050","article-title":"Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database","volume":"86","author":"Bettuzzi T","year":"2022","unstructured":"Bettuzzi T, Drucker A, Staumont-Sall\u00e9 D, Bihan K, Lebrun-Vignes B, Sbidian E. Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database. J Am Acad Dermatol. 2022, 86:431-3. 10.1016\/j.jaad.2021.09.050","journal-title":"J Am Acad Dermatol"},{"key":"ref6","unstructured":"DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use. (2022). Accessed. September 29, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s046lbl.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman JJ","year":"2016","unstructured":"Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016, 16:481-5. 10.7861\/clinmedicine.16-5-481","journal-title":"Clin Med (Lond)"},{"key":"ref8","article-title":"Abdominal pain","author":"Walls RM","year":"2022","unstructured":"Walls RM, Hockberger RS, Gausche-Hill M, Erickson TB, Wilcox SR. Abdominal pain. Rosen\u2019s Emergency Medicine: Concepts and Clinical Practice. Martinez JP (ed): Elsevier- Health Sciences Division, Philadelphia, PA; 2022. 211-20."},{"key":"ref9","article-title":"Serum sickness-like reaction in children: review of the literature","volume":"7","author":"Del Pozzo-Maga\u00f1a BR","year":"2019","unstructured":"Del Pozzo-Maga\u00f1a BR, Lazo-Langner A. Serum sickness-like reaction in children: review of the literature. EMJ Dermatol. 2019, 7:106-11.","journal-title":"EMJ Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona V","year":"2020","unstructured":"Cardona V, Ansotegui IJ, Ebisawa M, et al.. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020, 13:100472. 10.1016\/j.waojou.2020.100472","journal-title":"World Allergy Organ J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records","volume":"59","author":"Wang C","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Int J Dermatol. 2020, 59:253-6. 10.1111\/ijd.14573","journal-title":"Int J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15415","article-title":"Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6\u2009years and above: retrospective chart analysis from a single tertiary care center","volume":"35","author":"Parmar NV","year":"2022","unstructured":"Parmar NV, Abdula MA, Al Falasi A, Krishna CV. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6\u2009years and above: retrospective chart analysis from a single tertiary care center. Dermatol Ther. 2022, 35:e15415. 10.1111\/dth.15415","journal-title":"Dermatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27670","article-title":"Dupilumab-associated eosinophilic granulomatosis with polyangiitis","volume":"14","author":"Persaud P","year":"2022","unstructured":"Persaud P, Karmali R, Sankar P, Majid M. Dupilumab-associated eosinophilic granulomatosis with polyangiitis. Cureus. 2022, 14:e27670. 10.7759\/cureus.27670","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0181-6","article-title":"Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials","volume":"7","author":"Simpson EL","year":"2017","unstructured":"Simpson EL. Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb). 2017, 7:243-8. 10.1007\/s13555-017-0181-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S133661","article-title":"Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis","volume":"13","author":"Eshtiaghi P","year":"2018","unstructured":"Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid. 2018, 13:13-20. 10.2147\/CE.S133661","journal-title":"Core Evid"},{"key":"ref16","unstructured":"Adverse events. surveillance for adverse events and medical errors. (2000). Accessed: February 9, 2000: https:\/\/www.gao.gov\/assets\/t-hehs-00-61.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/194142-managing-a-patient-presenting-with-chest-pain-and-gastrointestinal-complaints-using-dupilumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:34Z","timestamp":1707509314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/194142-managing-a-patient-presenting-with-chest-pain-and-gastrointestinal-complaints-using-dupilumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.46478","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}